RE-BVS – Piemonte Repository

Sfoglia per AUTORE
LA VERDE N
Collezione AOU Città della Salute di Torino

Items : 11

Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. in NPJ breast cancer / NPJ Breast Cancer. 2024 Feb 5;10(1):13. doi: 10.1038/s41523-024-00619-5.

2024
AOU Città della Salute di Torino

Caldara A; Fontana A; Haspinger ER; Verderame F; Franco A; Valerio MR; Beano A; Raffaele M; Criscitiello C; Curigliano G; Guarino S; Pedersini R; Strina C; La Verde N; Savastano MC; Fuso P; Paris I; Botticelli A; Carbognin L; Fabi A; Di Leone A; Tortora G; Giannarelli D; Scambia G;

Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. in NPJ breast cancer / NPJ Breast Cancer. 2023 Sep 8;9(1):73. doi: 10.1038/s41523-023-00579-2.

2023
AOU Città della Salute di Torino

Fabi A; Carbognin L; Botticelli A; Paris I; Fuso P; Savastano MC; La Verde N; Strina C; Pedersini R; Guarino S; Curigliano G; Criscitiello C; Raffaele M; Beano A; Franco A; Valerio MR; Verderame F; Fontana A; Haspinger ER; Caldara A; Di Leone A; Tortora G; Giannarelli D; Scambia G;

2023
AOU Città della Salute di Torino

Patient associations and clinical oncology research: how much does a patient's voice really matter? in Expert review of pharmacoeconomics & outcomes research / Expert Rev Pharmacoecon Outcomes Res. 2021 Jun;21(3):433-440. doi: 10.1080/14737167.2021.1850274. Ep

2021
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

La Verde N; Nanni O; Procopio G; Adamo V; Cenna R; Nicolis F; Frazzetto AME; Gori S; Di Costanzo A; Arizio F; Franchina V; Cagnazzo C;

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. in Breast care (Basel, Switzerland) / Breast Care (Basel). 2020 Feb;15(1):30-37. doi: 10.1159/000495469. Epub 2019 Apr 17.

2020
AOU Città della Salute di Torino

Biganzoli L; Donadio M; Giordano M; Clivio L; Scavelli C; Frassoldati A; Palumbo R; Ferzi A; Schirone A; Gebbia V; Fabi A; Santini D; Porpiglia M; Turletti A; Atzori F; De Laurentiis M; Blasi L; Artale S; Bianchi GV; La Verde N; Mentuccia L; Maur M; Vici P; Musolino A; Garrone O; Pistelli M; Generali D; Febbraro A; Zambelli A; et alii...

Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ? 65 years: new lessons for clinical practice from the EVA study. in Oncotarget / Oncotarget. 2018 Oct 2;9(77):34639-34640. doi: 10.18632/oncotarget.26213. eCollection 2018 Oct 2.

2018
ASL Città di Torino
AOU Città della Salute di Torino

Fabi A; Cursano MC; Benedetto C; Turletti A; Atzori F; Piezzo M; Artale S; Blasi L; Bianchi G; La Verde N; Mentuccia L; Maur M; Vici P; Musolino A; Garrone O; Pistelli M; Generali D; Febbraro A; Zambelli A; Diodati L; Arcangeli V; Ficorella C; Moretti G; Airoldi M; Sartori D; Valerio MR; Fumagalli A; Ciccarese M; Verusio C; et alii...

Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ? 65 years: new lessons for clinical practice from the EVA study. in Oncotarget / Oncotarget. 2018 Nov 30;9(94):36720-36721. doi: 10.18632/oncotarget.26431. eCollection 2018 Nov 30.

2018
ASL Città di Torino
AOU Città della Salute di Torino

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ? 65 years: new lessons for clinical practice from the EVA study. in Oncotarget / Oncotarget. 2018 Aug 7;9(61):31877-31887. doi: 10.18632/oncotarget.25874. eCollection 2018 Aug 7.

2018
ASL Città di Torino
AOU Città della Salute di Torino

Cursano MC; Benedetto C; Turletti A; Atzori F; Piezzo M; Blasi L; Artale S; Bianchi G; La Verde N; Mentuccia L; Maur M; Vici P; Musolino A; Garrone O; Pistelli M; Generali D; Febbraro A; Zambelli A; Diodati L; Arcangeli V; Ficorella C; Moretti G; Airoldi M; Ancona C; Valerio MR; Sartori D; Fumagalli A; Ciccarese M; Verusio C; et alii...

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study. in Breast (Edinburgh, Scotland) / Breast. 2017 Oct;35:115-121. doi: 10.1016/j.breast.2017.06.043. Epub 2017 Jul 13.

2017
ASL Città di Torino
AOU Città della Salute di Torino

Sartori D; Scavelli C; Porpiglia M; Pistelli M; Palumbo R; Musolino A; Moretti G; Michelotti A; Maur M; La Verde N; Generali D; Gebbia V; Garrone O; Frassoldati A; Fumagalli A; Ficorella C; Ferzi A; Ferrari L; Fabi A; Piezzo M; Cursano MC; Ciccarese M; Campidoglio S; Blasi L; Bianchi GV; Ballerio A; Atzori F; Artale S; Arcangeli V; et alii...

Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology. in Tumori / Tumori. 2016 Jan-Feb;102(1):108-13. doi: 10.5301/tj.5000383. Epub 2015 Jul 2.

2016
AOU Città della Salute di Torino

Redana S; Luppi G; Amadio P; Ciuffreda L; Orlando L; Loupakis F; Gebbia V; Marcon I; Di Fabio F; Del Mastro L; Rossi A; Banna GL; La Verde N; Atzori F; Lunardi G; Torri V; Coati F; Pruneri G; Nolè F; Gori S; Aurilio G; Filippelli G; Gentile A; Collovà E;

Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life. in SpringerPlus / Springerplus. 2016 Jan 21;5:59. doi: 10.1186/s40064-016-1700-0. eCollection 2016.

2016
ASL Asti
AOU Città della Salute di Torino

Oletti MV; Polimeni MA; Lucio F; Donadio M; De Conciliis E; Airoldi M; Vandone AM; La Verde N; Saggia C; Montemurro F; Garrone O; Giacobino A; Merlano MC;